Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Decreases By 35.9%

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 170,700 shares, a drop of 35.9% from the January 31st total of 266,500 shares. Based on an average daily volume of 400,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.0% of the shares of the company are short sold.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd raised its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,903 shares of the company’s stock after acquiring an additional 48,977 shares during the quarter. XTX Topco Ltd owned 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent filing with the SEC. 10.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Sensei Biotherapeutics in a research note on Wednesday, January 8th.

Sensei Biotherapeutics Trading Up 6.2 %

Shares of SNSE opened at $0.47 on Friday. The stock’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.52. Sensei Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.94. The firm has a market capitalization of $11.72 million, a PE ratio of -0.39 and a beta of 0.17.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.